Insilico announces the expansion of its oncology pipelines and delivers the new generation FGFR2/3 inhibitor
- The nomination of the new generation of FGFR2/3 inhibitor for the treatment of tissue-agnostic solid tumors, bringing the total number of PCCs nominated by...